MAP2K7 and lung cancer: More importantly, we found that the combined use of PD-L1 Ab and the MEK/Erk inhibitor together significantly enhanced the NK cytotoxic effect to cisplatin-resistant lung cancer cells than using the PD-L1 Ab or the inhibitor alone.